NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

iBio, Inc. (IBIO) Stock Analysis

iBio, Inc. (IBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IBIO

$1.31

+$0.01 (+0.77%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IBIO with… →

IBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$1.29
Previous Close
$1.30
Day's Range
1.28–1.33
52-Week Range
0.77–3.82
Volume
265.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.29
Valuation
Market Cap
$84.24M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
842.43
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.32
Financials (FY)
Revenue (FY)
$400.00K+77.78%
Net Income (FY)
−$18.38M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.31M
1-Year Return
+61.73%
Dividend and dates
Avg Volume
842.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−32.12%
2025−21.22%
2024+78.83%
2023−84.43%
2022−96.80%
2021−47.62%
2020+320.00%
2019−66.67%
2018−58.33%
2017−55.00%
2016 (partial year)−42.03%

As of September 4, 2026.

IBIO Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$400.00K−$18.38M−4594.3%
2024$225.00K−$24.91M−11069.8%
2023$0.00−$65.01M—
2022$1.88M−$50.39M−2674.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$400.00K—−$18.60M−$18.38M−4594.3%
2024$225.00K—−$16.63M−$24.91M−11069.8%
2023$0.00—−$29.34M−$65.01M—
2022$1.88M$2.17M−$29.70M−$50.39M−2674.7%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

IBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricIBIOBiotechnology medianvs median
P/S ratio842.4315.2655.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

iBio, Inc. (IBIO) is capitalised at $84.24M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 23.

The 52-week range on file runs from $0.77 to $3.82. IBIO last closed at $1.31 on September 4, 2026. That is +$0.01 (+0.77%) against the previous close. The latest close sits 70.13% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $400.00K. Against the prior fiscal year total of $225.00K, that is a change of +77.78%. The same year closed with a net loss of $18.38M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.32.

Across the 4 fiscal years on file, revenue moves from $1.88M in 2022 to $400.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 842.43. On price-to-sales that is 55.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +61.73%. Measured over 10 years, that is −53.79% a year compounded. Beta against the wider market is reported at 1.29. Daily returns over the trailing 10 years annualize to a volatility of 157.2%.

Growth & Income

No dividend is on file for IBIO.

Across the complete calendar years on file, 2020 returned +320.00% and 2022 returned −96.80%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −32.12% year to date.

Peer Comparison

iBio, Inc. (IBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
iBio, Inc. IBIO $84.24M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. iBio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About iBio, Inc.

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Visit website →